Table 1 Patient background

Age, years

65.4 ± 14.4

Female, %

80.7

Disease duration, months

103.6 ± 119.6

Stage (I/II/III/IV), %

44.7/26.7/14.7/13.9

TJC, 0–28

2.9 ± 4.2

SJC, 0–28

1.7 ± 3.2

CRP, mg/dL

0.8 ± 1.8

ESR, mm/h

24.4 ± 24.7

RF, IU/mL

121.8 ± 216.8

RF positive, %

61.2

CCP, U/mL

250.9 ± 405.3

CCP positive, %

66.5

MMP-3, ng/mL

131.6 ± 229.6

SDAI

10.6 ± 11.7

MTX use, %

63.7

MTX, mg/w

8.7 ± 3.4

PSL use, %

12.7

PSL, mg/d

4.7 ± 3.4

b(ts)DMARD use, %

37.7

HAQ-DI

0.8 ± 0.9

EQ-5D-5L

0.7 ± 0.2

MS, min

145.0 ± 398.6

Pain VAS score, 0–100, mm

31.2 ± 29.1

Fatigue VAS score, 0–100, mm

32.4 ± 29.8

EGA, 0–100, mm

16.4 ± 19.1

GS sum

3.1 ± 5.1

GS score ≥ 1, %

65.7

GS score ≥ 2, %

36.0

GS score ≥ 3, %

14.3

PD sum

1.3 ± 3.0

PD score ≥ 1, %

34.0

PD score ≥ 2, %

22.7

PD score ≥ 3, %

2.7